Most common reasons for KI discontinuation in patients who have discontinued ibrutinib or idelalisib
| . | Ibrutinib % (n) . | Idelalisib % (n) . |
|---|---|---|
| Toxicity | 51 (73) | 52 (18) |
| CLL progression | 28 (40) | 31 (11) |
| RT | 8 (11) | 6 (2) |
| Cellular therapies (chimeric antigen receptor T cells or allogeneic stem cell transplantation) | 2 (3) | 0 (0) |
| Unrelated death/Other | 11 (16) | 11 (4) |
| . | Ibrutinib % (n) . | Idelalisib % (n) . |
|---|---|---|
| Toxicity | 51 (73) | 52 (18) |
| CLL progression | 28 (40) | 31 (11) |
| RT | 8 (11) | 6 (2) |
| Cellular therapies (chimeric antigen receptor T cells or allogeneic stem cell transplantation) | 2 (3) | 0 (0) |
| Unrelated death/Other | 11 (16) | 11 (4) |